Tech Center 4100 • Art Units: 1600 1632 1641 1642 1643 1644 1645 1646 1647 1654
This examiner grants 26% of resolved cases
Joanne Hama is an examiner in Tech Center 4100, assigned to Art Unit 1600. With 262 resolved cases, the examiner has a well-documented history of prosecution. The allowance rate is 25.6 percent, which is notably low and indicates a challenging environment for securing a patent grant. This 25.6 percent rate suggests that the majority of applications in this docket do not reach allowance, requiring a very high standard of patentability.
The median days to allowance is 1342, reflecting a long prosecution process. This 1342-day timeline is a significant consideration for applicants in Art Unit 1600. However, the interview lift percentage is 38.2, which is a very positive sign. This 38.2 percent lift indicates that interviews are highly effective at improving the odds of an allowance, even in a difficult prosecution environment. Given the low 25.6 percent baseline allowance rate, the 38.2 percent lift suggests that direct engagement is a highly effective way to move a case toward a grant. Practitioners in Tech Center 4100 should be prepared for the 1342-day median pendency and should strongly consider using interviews to overcome the hurdles indicated by the 25.6 percent allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18294767 | METHODS TO ENHANCE EFFICACY OF COMBINED TARGETING OF IMMUNE CHECKPOINT AND MAPK PATHWAYS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18042989 | METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18123112 | CAR CELLS TARGETING AN INSERTED LIGAND | Final Rejection | Massachusetts Institute of Technology |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | Non-Final OA | Gilead Sciences, Inc. |
| 18127284 | COMPOSITIONS AND METHODS FOR PRODUCING AND USING ILCS TO TREAT HEALTH CONDITIONS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18424004 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH | Non-Final OA | Novartis AG |
| 18322395 | PURIFICATION OF ANTIBODY DRUG CONJUGATES USING A SODIUM PHOSPHATE GRADIENT | Non-Final OA | PFIZER INC. |
| 18360542 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | Non-Final OA | MedImmune, LLC |
| 18193958 | METHODS OF TREATING ENHANCING BRAIN TUMORS USING COMBINATION THERAPY | Non-Final OA | Servier Pharmaceuticals LLC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy